Antithrombotic Therapy for Patients Undergoing Cardiac Electrophysiological and Interventional Procedures: JACC State-of-the-Art Review.
Di Biase L, Lakkireddy DJ, Marazzato J, Velasco A, Diaz JC, Navara R, Chrispin J, Rajagopalan B, Natale A, Mohanty S, Zhang X, Della Rocca D, Dalal A, Park K, Wiley J, Batchelor W, Cheung JW, Dangas G, Mehran R, Romero J; ACC Electrophysiology and Interventional Councils.
J Am Coll Cardiol. 2024 Jan 2;83(1):82-108. doi: 10.1016/j.jacc.2023.09.831.
Comparison of anticoagulation with left atrial appendage closure after atrial fibrillation ablation: Rationale and design of the OPTION randomized trial.
Wazni OM, Boersma L, Healey JS, Mansour M, Tondo C, Phillips K, Doshi R, Jaber W, Hynes E, Allocco DJ, Reddy VY.
Am Heart J. 2022 Sep;251:35-42. doi: 10.1016/j.ahj.2022.05.003. Epub 2022 May 6.
Surgical ablation supplemented by ethanol injection for ventricular tachycardia refractory to percutaneous ablation.
Yang G, Shao Y, Gu W, Ni B, Yang B, Zhang F, Ju W, Chen H, Gu K, Li M, Chen Y, Sun H, Tam TK, Wu Y, Chen M.
J Cardiovasc Electrophysiol. 2021 Sep;32(9):2462-2470. doi: 10.1111/jce.15162. Epub 2021 Jul 21.
Complications and Anticoagulation Strategies for Percutaneous Epicardial Ablation Procedures.
Nakamura T, Davogustto GE, Schaeffer B, Tanigawa S, Muthalaly RG, Kanagasundram A, John RM, Michaud GF, Tedrow UB, Stevenson WG.
Circ Arrhythm Electrophysiol. 2018 Nov;11(11):e006714. doi: 10.1161/CIRCEP.118.006714.
Cardiac troponin I degradation in serum of patients with hypertrophic obstructive cardiomyopathy undergoing percutaneous septal ablation.
Madsen LH, Lund T, Grieg Z, Nygaard S, Holmvang L, Jurlander B, Grande P, Christensen G, Atar D.
Cardiology. 2009;114(3):167-73. doi: 10.1159/000226596. Epub 2009 Jul 2.
Practical considerations for using novel oral anticoagulants in patients with atrial fibrillation.
Savelieva I, Camm AJ.
Clin Cardiol. 2014 Jan;37(1):32-47. doi: 10.1002/clc.22204. Epub 2013 Nov 19.
Update on Direct Oral Anticoagulants in Atrial Fibrillation Patients Undergoing Cardiac Interventional Procedures: From Clinical Trials to Real-World Evidence.
Melillo E, Carbone A, Rago A, Papa AA, D' Onofrio A, Nigro G, Golino P, Russo V.
J Cardiovasc Pharmacol. 2020 Mar;75(3):185-199. doi: 10.1097/FJC.0000000000000786.
Retrospective Analysis of Risk Factors for Related Complications of Chemical Ablation on Hypertrophic Obstructive Cardiomyopathy.
Li CY, Shi YQ.
Arq Bras Cardiol. 2019 Apr;112(4):432-438. doi: 10.5935/abc.20190060. Epub 2019 Apr 1.
Air Embolism after Percutaneous Lung Biopsy or Ablation: A Report of Six Cases.
Choi R, Phan HK, Gurusamy V, Sheth RA, Odisio BC, Hong K, Tam AL.
Radiol Imaging Cancer. 2025 May;7(3):e240379. doi: 10.1148/rycan.240379.
Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances.
Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H.
Int J Cardiol. 2007 Jul 10;119(2):163-7. doi: 10.1016/j.ijcard.2006.07.179. Epub 2006 Oct 24.
